- Biodexa Pharmaceuticals (BDRX, Financial) schedules a General Meeting for May 2, 2025, at its Cardiff offices.
- Key resolutions include share subdivision, a new directors' remuneration policy, and the adoption of new articles of association.
- The changes aim to reduce the par value of shares, facilitating issuance above par value without affecting the number of outstanding shares.
Biodexa Pharmaceuticals (Nasdaq: BDRX) has announced a General Meeting to be held on May 2, 2025, at 13:00 BST at their Cardiff offices. The agenda will include three key resolutions aimed at optimizing company operations and shareholder value.
The first resolution proposes the subdivision of each issued ordinary share, reducing its par value from £0.00005 to £0.000001. This will transform each share into one ordinary share and 49 D deferred shares, both valued at £0.000001. The primary objective is to lower the share's par value, allowing the company to issue shares above this threshold. Importantly, this adjustment will not alter the total number of ordinary shares or American Depositary Shares outstanding.
Another resolution will focus on the approval of a new directors' remuneration policy, which is detailed in the General Meeting's documentation. Additionally, the meeting will include a vote to adopt new articles of association, with the draft available on the company's website.
Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing innovative treatments for diseases with unmet medical needs. The resolutions proposed at this meeting could play a significant role in supporting the company's strategic and operational goals.
